SCHEMBL23574148

SCHEMBL23574148

N#Cc1cccc(-c2cnc(N3CCN4CCN(C#N)C[C@H]4C3=O)nc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 8/20 0.52
OTUD7B Q6GQQ9 3/20 0.42
MET P08581 1/20 0.40
BACE1 P56817 5/20 0.39
CYP2C9 P11712 3/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP1A2 P05177 3/20 0.39
CASP1 P29466 3/20 0.39
CASP7 P55210 3/20 0.39
TSHR P16473 2/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39
CYP3A4 P08684 4/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP2D6 P10635 1/20 0.39
MEN1 O00255 1/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23573999 1.00 USP30 (0.52) USP30OTUD7BMETBACE1CYP2C9
SCHEMBL23574000 1.00 USP30 (0.52) USP30OTUD7BMETBACE1CYP2C9
SCHEMBL30801915 0.88 USP30 (0.42) USP30BACE1CYP3A4
SCHEMBL30801907 0.88 USP30 (0.42) USP30BACE1CYP3A4
SCHEMBL23113592 0.88 USP30 (0.42) USP30BACE1CYP3A4
SCHEMBL23113755 0.88 USP30 (0.42) USP30BACE1CYP3A4
SCHEMBL23574052 0.88 USP30 (0.42) USP30BACE1CYP3A4
SCHEMBL23574119 0.85 USP30 (0.49) USP30OTUD7BBACE1
SCHEMBL23574121 0.85 USP30 (0.49) USP30OTUD7BBACE1
SCHEMBL30986847 0.85 USP30 (0.49) USP30OTUD7BBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12049466-B2 Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-30 US claimed
EP-3793997-B1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-03-13 EP claimed
US-12049466-B2 Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-30 US disclosed
CN-112513036-B Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors 福马治疗有限公司 2024-05-24 CN disclosed
EP-3793997-B1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-03-13 EP disclosed
US-20210198263-A1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2021-07-01 US disclosed
US-20210198263-A1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2021-07-01 US disclosed
CN-112513036-A Fused bicyclic compounds as ubiquitin-specific peptidase 30 inhibitors 福马治疗有限公司 2021-03-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198263-A1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS USP30, UCHL1, ADRM1 USP30 1/4885OTUD7B 593/4885MET 3729/4885
US-12049466-B2 Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors USP30, UCHL1, ADRM1 USP30 1/4885OTUD7B 593/4885MET 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.